Click here to see slides

Table of Contents

�Mean steady-state saquinavir plasma concentration in HIV-infected subjects Study NV15107
�Exposure–response (2 parameter Emax model) for saquinavir-SGCStudy NV15107
�Effect of saquinavir-SGC on the pharmacokinetics of co-administered drugs
�Effect of co-administered drugs on saquinavir pharmacokinetics
�Percentage of individuals experiencing clinical adverse eventsa in studies NV15182 and NV15355
�Percentage of individuals with marked laboratorya abnormalities in studies NV15182 and NV15355
�Proportion of subjects <400 copies/mL Study NV15355
�Proportion of subjects <50 copies/mL Study NV15355
�HIV-1 RNA and CD4 changes in value over time for standard population SUN study
�Virological response after 24 weeks of the CHEESE study
�CD4+ T-cell response after 24 weeks of the CHEESE study
�Proportion below limit of quantification UltraSensitive (<50 copies/mL); ITT
�Proportion below limit of quantification UltraSensitive (<50 copies/mL); OT
�Proportion below limit of quantification Patients crossed over to SQV+NFV+2nRTIs; OT
�TIBID Study: Propotion of subjects <400 copies/mL; OT & ITT
�TIBID Study: Proportion of subjects <50 copies/mL; OT & ITT
�Proportion of subjects <400 copies/mL (Amplicor) and <50 copies/mL (UltraSensitive) NV15545 Part 1, All Patients, ITT
�Mean nonfasting serum triglyceride M61018 (TIDBID)
�Mean nonfasting serum triglyceride SWITCH study
�Mean fasting serum triglyceride in healthy volunteers